基于肠促胰岛素的药物的研究进展

The research progress of incretin-based drugs

基于肠促胰岛素的药物包括胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂和二肽基肽酶-4抑制剂,目前已获准用于治疗2型糖尿病,而其未来的发展方向可能主要在于如何优化自身特点和扩展临床适应证,具体包括延长GLP-1受体激动剂的有效作用时间、开发能口服的GLP-1受体激动剂、寻找可促进GLP-1分泌的新靶点、开发其他胃肠-胰腺生物活性肽类新药以及探求此类药物在1型糖尿病、肥胖症、心血管疾病和神经退行性疾病治疗领域中的临床应用前景等。

Incretin-based drugs include glucagon-like peptide-1 （GLP-1） receptor agonists and dipeptidyl peptidase-4 inhibitors, which are permitted to be used for treating the type 2 diabetes at present and their future development mainly focuses on the optimization and expand their clinical indications, including prolonging the effective duration, manufacturing oral agents and searching for the new target to stimulate the secretion of GLP-1 receptor agonists. Other gastrointestinal-pancreas bioactive peptide type drugs will be developed and their prospects of clinical application in treatment of type 1 diabetes, obesity, cardiovascular and neurodegenerative diseases are explored.